Atossa Genetics (NASDAQ: ATOS) is one of 120 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Atossa Genetics to related companies based on the strength of its dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Valuation & Earnings

This table compares Atossa Genetics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Atossa Genetics N/A -$11.40 million -0.51
Atossa Genetics Competitors $1.48 billion $146.48 million 43.94

Atossa Genetics’ rivals have higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Atossa Genetics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics 0 0 2 0 3.00
Atossa Genetics Competitors 799 2804 4975 252 2.53

Atossa Genetics presently has a consensus target price of $9.50, indicating a potential upside of 241.73%. As a group, “Surgical & medical instruments” companies have a potential upside of 21.87%. Given Atossa Genetics’ stronger consensus rating and higher possible upside, analysts clearly believe Atossa Genetics is more favorable than its rivals.

Insider & Institutional Ownership

13.9% of Atossa Genetics shares are held by institutional investors. Comparatively, 50.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 3.1% of Atossa Genetics shares are held by insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Atossa Genetics has a beta of 3.82, meaning that its stock price is 282% more volatile than the S&P 500. Comparatively, Atossa Genetics’ rivals have a beta of 1.12, meaning that their average stock price is 12% more volatile than the S&P 500.


This table compares Atossa Genetics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atossa Genetics N/A -172.50% -94.42%
Atossa Genetics Competitors -30.00% -41.48% -13.59%


Atossa Genetics rivals beat Atossa Genetics on 8 of the 13 factors compared.

Atossa Genetics Company Profile

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.